Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of "Hold" by Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) have received a consensus rating of "Hold" from the twenty ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, sixteen have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $10.53.

A number of research firms recently commented on SAGE. Raymond James reaffirmed a "market perform" rating on shares of Sage Therapeutics in a research note on Thursday, October 10th. Robert W. Baird decreased their target price on shares of Sage Therapeutics from $13.00 to $9.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 9th. Piper Sandler cut their price target on Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, January 2nd. Oppenheimer decreased their price objective on Sage Therapeutics from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Wednesday, October 30th. Finally, Stifel Nicolaus decreased their price target on Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating on the stock in a research note on Monday, December 16th.

Sage Therapeutics Stock Performance

NASDAQ:SAGE traded down $0.30 during trading hours on Friday, hitting $5.55. The company's stock had a trading volume of 1,172,620 shares, compared to its average volume of 1,200,950. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $28.26. The business's 50-day moving average is $5.57 and its two-hundred day moving average is $7.60. The company has a market capitalization of $339.51 million, a PE ratio of -0.99 and a beta of 0.91.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The company had revenue of $11.87 million for the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The company's quarterly revenue was up 337.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.81) earnings per share. As a group, analysts predict that Sage Therapeutics will post -6.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Sage Therapeutics

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its position in Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock worth $8,975,000 after purchasing an additional 3,757 shares during the last quarter. State Street Corp increased its position in Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock valued at $21,127,000 after acquiring an additional 451,377 shares during the period. RTW Investments LP raised its stake in Sage Therapeutics by 2.0% during the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company's stock valued at $40,372,000 after acquiring an additional 111,123 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Sage Therapeutics during the 3rd quarter worth $208,000. Finally, Martingale Asset Management L P grew its stake in shares of Sage Therapeutics by 55.1% in the third quarter. Martingale Asset Management L P now owns 47,077 shares of the biopharmaceutical company's stock worth $340,000 after purchasing an additional 16,717 shares in the last quarter. Institutional investors own 99.22% of the company's stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.